Search icon

MORPHOGENESIS, INC. - Florida Company Profile

Headquarter
Company claim

Is this your business?

Get access!

Company Details

Entity Name: MORPHOGENESIS, INC.
Jurisdiction: FLORIDA
Filing Type: Domestic Profit

MORPHOGENESIS, INC. is structured as a Domestic Profit Corporation, which, in Florida signifies a Profit Corporation (also known as a C-Corporation). This business structure is recognized as a separate legal entity from its owners. This offers shareholders the benefit of limited liability protection, safeguarding their personal assets from the corporation's debts and obligations, and facilitates raising capital through the issuance of stock. In Florida, Domestic Profit Corporations are governed by Title XXXVI, Chapter 607, Florida Statutes – Florida Business Corporation Act.

Status: Inactive

The business entity is inactive. This status may signal operational issues or voluntary closure, raising concerns about the business's ability to repay loans and requiring careful risk assessment by lenders.

Date Filed: 15 May 1995 (30 years ago)
Date of dissolution: 27 Apr 2023 (2 years ago)
Last Event: DOMESTICATED
Event Date Filed: 27 Apr 2023 (2 years ago)
Document Number: P95000039037
FEI/EIN Number 593359711

Federal Employer Identification (FEI) Number assigned by the IRS.

Address: 10500 University Center Drive, TAMPA, FL, 33612, US
Mail Address: 10500 University Center Drive, TAMPA, FL, 33612, US
ZIP code: 33612
County: Hillsborough
Place of Formation: FLORIDA

Links between entities

Type:
Headquarter of
Company Number:
5204758
State:
NEW YORK
NEW YORK profile:

Key Officers & Management

Name Role Address
Lawman Patricia Director 10500 University Center Drive, TAMPA, FL, 33612
Lawman Michael Director 10500 University Center Drive, TAMPA, FL, 33612
Bianco James Chief Executive Officer 10500 University Center Drive, TAMPA, FL, 33612
Dearborn Dan Chief Financial Officer 10500 University Center Drive, TAMPA, FL, 33612
Patel Kiran C Chairman 10500 University Center Drive, TAMPA, FL, 33612
Ng George Director 10500 University Center Drive, TAMPA, FL, 33612
Dearborn Dan Agent 10500 University Center Drive, TAMPA, FL, 33612

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
4FJK7
Status:
Obsolete
Type:
Non-Manufacturer
CAGE Update Date:
2024-10-30
SAM Expiration:
2024-10-30

Contact Information

POC:
DAN DEARBORN

Events

Event Type Filed Date Value Description
DOMESTICATED 2023-04-27 - -
AMENDED AND RESTATEDARTICLES 2022-06-24 - -
REGISTERED AGENT ADDRESS CHANGED 2022-04-25 10500 University Center Drive, Suite 100, TAMPA, FL 33612 -
REGISTERED AGENT NAME CHANGED 2022-04-25 Dearborn, Dan -
AMENDMENT 2022-03-24 - -
AMENDMENT 2021-07-16 - -
AMENDED AND RESTATEDARTICLES 2020-12-15 - -
AMENDED AND RESTATEDARTICLES 2018-04-18 - -
CHANGE OF MAILING ADDRESS 2018-02-28 10500 University Center Drive, Suite 100, TAMPA, FL 33612 -
CHANGE OF PRINCIPAL ADDRESS 2018-02-28 10500 University Center Drive, Suite 100, TAMPA, FL 33612 -

Court Cases

Title Case Number Docket Date Status
SHABNAM EIDIZADEH VS ST. JOSEPH'S HEALTH CARE CENTER, INC., ET AL 2D2015-2946 2015-07-02 Closed
Classification NOA Final - Circuit Civil - Other
Court 2nd District Court of Appeal
Originating Court Circuit Court for the Thirteenth Judicial Circuit, Hillsborough County
12-009072

Parties

Name SHABNAM EIDIZADEH
Role Appellant
Status Active
Representations LINDSEY C. KOFOED, ESQ., WOLFGANG FLORIN, ESQ., CHRISTOPHER D. GRAY, ESQ., ROBIN M. OROSZ, ESQ.
Name BAYCARE HEALTH SYSTEM, INC.
Role Appellee
Status Active
Name MORPHOGENESIS, INC.
Role Appellee
Status Active
Name ST. JOSEPH'S HEALTH CARE CTR.
Role Appellee
Status Active
Name HILLSBOROUGH CLERK
Role Lower Tribunal Clerk
Status Active

Docket Entries

Docket Date 2015-07-21
Type Disposition
Subtype Dismissed
Description Dismissed - Order by Clerk
Docket Date 2015-07-21
Type Disposition by Order
Subtype Dismissed
Description ORDER GRANTING VOLUNTARY DISMISSAL
Docket Date 2015-07-17
Type Motions Other
Subtype Motion/Notice Voluntary Dismissal
Description Notice of Voluntary Dismissal
On Behalf Of SHABNAM EIDIZADEH
Docket Date 2015-07-08
Type Order
Subtype Order on Filing Fee
Description fee - civil; atty
Docket Date 2015-07-02
Type Misc. Events
Subtype Fee Status
Description HL:Fee Owed
Docket Date 2015-07-02
Type Notice
Subtype Notice of Appeal
Description Notice of Appeal Filed
On Behalf Of SHABNAM EIDIZADEH
Docket Date 2015-07-02
Type Miscellaneous Document
Subtype Lower Tribunal Transmittal Cover Sheet
Description LOWER TRIBUNAL TRANSMITTAL COVER SHEET
On Behalf Of HILLSBOROUGH CLERK

Documents

Name Date
Domestication 2023-05-02
ANNUAL REPORT 2023-03-20
Amended and Restated Articles 2022-06-24
ANNUAL REPORT 2022-04-25
Amendment 2022-03-24
Amendment 2021-07-16
ANNUAL REPORT 2021-01-29
Amended and Restated Articles 2020-12-15
ANNUAL REPORT 2020-03-23
ANNUAL REPORT 2019-04-19

USAspending Awards / Financial Assistance

Date:
2021-04-30
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
A LOW-COST TOPICAL IMMUNOTHERAPY FORMULATION SUITABLE FOR TREATING CERVICAL CANCER IN LOW AND MIDDLE INCOME COUNTRIES AND LOW-RESOURCE SETTINGS IN THE U.S. - THE GOAL OF THIS PROJECT IS TO DELIVER AN AFFORDABLE IMMUNOTHERAPY TO TREAT ADVANCED CERVICAL CANCER IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS) AND LOW-RESOURCE SETTINGS IN THE U.S. A LONGER-TERM GOAL IS TO TREAT EARLIER STAGES OF CERVICAL DYSPLASIA AND ASSESS IMMUNITY TO THE CAUSATIVE AGENT, HUMAN PAPILLOMAVIRUS (HPV). THE HEAVY BURDEN OF SUFFERING AND DEATH FROM CERVICAL CANCER DISPROPORTIONATELY FALLS ON WOMEN IN RESOURCE POOR SETTINGS. OVERCOMING BARRIERS TO TREATMENT, I.E. LACK OF INFRASTRUCTURE, TRAINED SPECIALISTS, SPECIALIZED EQUIPMENT, COLD CHAIN, AND FINANCIAL RESOURCES, REQUIRES A PARADIGM SHIFT IN THE APPROACH TO TREATMENT THAT CAN BE ACHIEVED BY THE INNOVATIVE IMMUNOTHERAPEUTIC AGENT PROPOSED HERE. IFX-HU2.1 (SN63/016,700) IS A CREAM-BASED THERAPEUTIC IMMUNOMODULATOR THAT WILL BE OPTIMIZED FOR STABILITY AND PERFORMANCE. OUR IFX-HU2 FAMILY CONTAINS A PLASMID DNA (PDNA) BULK DRUG SUBSTANCE, WHICH CAN BE PRODUCED FOR A FRACTION OF THE COST OF CURRENT IMMUNOTHERAPIES. THE PDNA ENCODES A COMPLEX BACTERIAL ANTIGEN, EMM55. WHEN EXPRESSED ON THE TUMOR CELL SURFACE, EMM55 ATTRACTS ANTIGEN PRESENTING CELLS AND OTHER CELLS OF THE INNATE IMMUNE RESPONSE. NON-SELF-EPITOPES SUCH AS TUMOR AND HPV ANTIGENS ARE THEN EXPOSED IN SUCH A WAY AS TO SET UP MULTI-ANTIGENIC CELLULAR AND HUMORAL ADAPTIVE IMMUNE RESPONSES. EMM55-BASED THERAPIES INDUCE PERSONALIZED, MULTIVALENT, SYSTEMIC, AND SUSTAINED IMMUNE RESPONSES AND HAVE THE POTENTIAL TO TREAT A BROAD RANGE OF CANCERS THROUGH ENHANCED TUMOR RECOGNITION, IMMUNE ACTIVATION AND EPITOPE SPREADING. INTRALESIONAL INJECTION OF IFX-HU2.0 HAS AN ESTABLISHED SAFETY PROFILE IN MULTIPLE ANIMAL STUDIES AND IS CURRENTLY BEING TESTED IN PHASE 1 HUMAN CLINICAL TRIALS FOR CUTANEOUS MELANOMA, MERKEL CELL CARCINOMA AND CUTANEOUS SQUAMOUS CELL CARCINOMA. OUR PRELIMINARY CLINICAL DATA CORROBORATE PRE-CLINICAL OBSERVATIONS, SHOWING THE ACTIVATION OF T- AND B-CELL IMMUNE RESPONSES AND TUMOR REDUCTION, WITH NO SHORT OR LONG-TERM ADVERSE EFFECTS. WE PROPOSE TO OPTIMIZE THE IFX-HU2.1 FORMULATION FOR TEMPERATURE STABILITY USING ESTABLISHED METHODS AND MODELS. IN VITRO EVALUATION, TO INCLUDE STANDARD QUALITY CONTROL METHODS AND A HUMAN VAGINAL EPITHELIUM CARCINOMA MODEL, WILL BE FOLLOWED BY IN VIVO UPTAKE, EXPRESSION, AND DISEASE PROGRESSION STUDIES IN A MOUSE MODEL OF CERVICAL CANCER. ROOM TEMPERATURE STORAGE AND SELF-ADMINISTRATION WILL CIRCUMVENT ONEROUS CLINIC VISITS, IMPROVE PROGNOSIS AND PRESERVE FERTILITY. IFX-HU2.1 CREAM FORMULATION WILL PROVIDE A NON-TOXIC CANCER THERAPEUTIC TREATMENT WITH MINIMAL SUPPORTIVE CARE REQUIREMENTS, FEATURING UNIQUE DELIVERY, AND HIGH APPLICABILITY/IMPACT TO UNDERSERVED POPULATIONS. THE DATA OBTAINED BY COMPLETING THESE STUDIES WILL POSITION MORPHOGENESIS, INC. TO SUBMIT AN INVESTIGATIONAL NEW DRUG APPLICATION TO CONDUCT A CLINICAL TRIAL FOR WOMEN IN A LOCAL COMMUNITY HOSPITAL (LOW-RESOURCE SETTING) AND IN SOUTH AFRICA (LMIC). THESE TRIALS WILL BE THE OBJECTIVE OF AN SBIR PHASE 2 PROPOSAL.
Obligated Amount:
400000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-02-09
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
294070.00
Total Face Value Of Loan:
294070.00
Date:
2020-04-11
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
404847.00
Total Face Value Of Loan:
404847.00

Paycheck Protection Program

Date Approved:
2020-04-10
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
404847
Current Approval Amount:
404847
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
409663.1
Date Approved:
2021-02-09
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
294070
Current Approval Amount:
294070
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
297432.2

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 02 Jun 2025

Sources: Florida Department of State